Clinical Trials

308 enrolled

Leukemia, Myeloid, Acute

NCT07007312 2026-04-09

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

1,300 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04102020 2026-04-08

VIALE-M

112 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT07407140 2026-03-25

VAG-3+7-G

300 enrolled

Leukemia, Myeloid, Acute

NCT07486479 2026-03-20

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

204 enrolled

Leukemia, Myeloid, Acute

NCT07478991 2026-03-18

VENP-A-QUI

376 enrolled

Leukemia, Myeloid, Acute

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

240 enrolled

Leukemia, Myeloid, Acute

NCT07407660 2026-02-12

Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

250 enrolled

Leukemia, Myeloid, Acute

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

167 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05183035 2026-01-13

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

98 enrolled

Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 4 FDA

Leukemia, Myeloid, Acute

NCT06389292 2025-11-25

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

486 enrolled

Leukemia, Myeloid, Acute

NCT06647862 2025-11-25

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

170 enrolled

Phase 3 Active not recruiting

Leukemia, Myelomonocytic, Chronic

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT03268954 2025-10-29

PANTHER

MyeloidOther hematologic neoplasm

454 enrolled 41 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04161885 2025-10-06

VIALE-T

Phase 3 Terminated

465 enrolled

Phase 3 Active not recruiting

Neoplasms, Leukemia, Myeloid, Acute

NCT04229979 2025-10-01

REGAL

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

183 enrolled 30 charts

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 3 FDA

Leukemia, Myeloid, Acute

NCT07082452 2025-07-24

SEVENAZA

LymphoidOther hematologic neoplasm

262 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

472 enrolled 24 charts 3 FDA

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02577406 2025-05-18

IDHENTIFY

319 enrolled 29 charts